Prolonged and potent therapeutic and prophylactic effects of (S)-1-[(3-hydroxy-2-phosphonylmethoxy)propyl]cytosine against herpes simplex virus type 2 infections in mice
about
sameAs
Brincidofovir (CMX001) inhibits BK polyomavirus replication in primary human urothelial cellsTreatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimineOral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.Transporter-targeted lipid prodrugs of cyclic cidofovir: a potential approach for the treatment of cytomegalovirus retinitis.Effects of phosphonylmethoxyalkyl derivatives studied with a murine model for abortion induced by equine herpesvirus 1.Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management.Effect of BV-araU and acyclovir on varicella-zoster virus replication with various length and timing of drug exposure.Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice.Cidofovir in the treatment of cytomegaloviral disease.
P2860
Q27324404-376A835B-1607-42C6-94C1-708B3634D6B6Q28326886-69876D9C-23F7-437C-8BBA-0851335719F8Q34483696-88D23DCE-A624-4E55-BD4F-90FE270BE1E7Q35558801-2B57926A-8ED5-42A7-B193-ED5ECC334881Q35892584-8FDDF0C0-CF47-472D-9652-6692DDF432B6Q35900309-EC4D8395-0626-4905-939C-7BC9A1C64920Q36478736-674B2CDE-3C59-4A4A-A252-B4B4D8AE8FB8Q41500769-2CB0C385-48DD-4CCE-9F00-3598456D382EQ48312954-8B1C15EE-C519-48CA-A581-C687F33E6A0AQ54115801-87F70F00-6D24-4551-AC62-009162065CA8
P2860
Prolonged and potent therapeutic and prophylactic effects of (S)-1-[(3-hydroxy-2-phosphonylmethoxy)propyl]cytosine against herpes simplex virus type 2 infections in mice
description
1991 nî lūn-bûn
@nan
1991 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Prolonged and potent therapeut ...... irus type 2 infections in mice
@ast
Prolonged and potent therapeut ...... irus type 2 infections in mice
@en
Prolonged and potent therapeut ...... irus type 2 infections in mice
@nl
type
label
Prolonged and potent therapeut ...... irus type 2 infections in mice
@ast
Prolonged and potent therapeut ...... irus type 2 infections in mice
@en
Prolonged and potent therapeut ...... irus type 2 infections in mice
@nl
prefLabel
Prolonged and potent therapeut ...... irus type 2 infections in mice
@ast
Prolonged and potent therapeut ...... irus type 2 infections in mice
@en
Prolonged and potent therapeut ...... irus type 2 infections in mice
@nl
P2860
P356
P1476
Prolonged and potent therapeut ...... irus type 2 infections in mice
@en
P2860
P304
P356
10.1128/AAC.35.8.1596
P407
P577
1991-08-01T00:00:00Z